Choline (DB00122): A Comprehensive Monograph on its Biochemical, Pharmacological, and Clinical Profile

Executive Summary

Choline, identified by DrugBank accession number DB00122, is a small molecule that transcends its classification as a simple nutraceutical. It is a cornerstone of human physiology, fundamentally essential for the structural integrity of every cell, the functional capacity of the nervous system, and the regulation of hepatic lipid metabolism. Its biological importance is rooted in a tripartite role: as an indispensable precursor for the synthesis of major membrane phospholipids like phosphatidylcholine and sphingomyelin; as the direct antecedent to the neurotransmitter acetylcholine, which governs memory, muscle control, and autonomic function; and as the substrate for the production of the methyl-donor betaine, linking it inextricably to one-carbon metabolism and epigenetic regulation.

This monograph provides an exhaustive analysis of choline, from its fundamental chemical properties to its complex clinical profile. A central theme that emerges is the clinical paradox of choline. On one hand, dietary deficiency leads to severe and demonstrable organ dysfunction, most notably non-alcoholic fatty liver disease (NAFLD) and myopathy. On the other hand, its therapeutic application is not straightforward and requires a nuanced understanding of an individual's genetic makeup, hormonal status, and gut microbiome composition. The form in which choline is consumed—whether as a water-soluble salt or a lipid-soluble phospholipid—profoundly impacts its pharmacokinetic profile, bioavailability, and metabolic fate, particularly concerning the generation of trimethylamine N-oxide (TMAO), a metabolite implicated in cardiovascular disease.

Current research frontiers are actively exploring choline's therapeutic potential in complex, multifactorial diseases. In neurodegeneration, particularly Alzheimer's disease, the scientific paradigm is shifting from a simple neurotransmitter replacement strategy to a more sophisticated model centered on choline's role in maintaining neuronal membrane integrity and lipid homeostasis. Clinical trials are underway to investigate its efficacy in NAFLD, fetal alcohol spectrum disorders, and even long-haul COVID-19. This report synthesizes the current body of evidence to provide a comprehensive and insightful overview of this vital molecule, highlighting its established roles, its therapeutic promise, and the critical scientific questions that remain to be answered.

Compound Profile and Chemical Properties

This section establishes the fundamental chemical identity of choline, providing the foundational knowledge necessary to understand its biological behavior, transport, and metabolic transformations.

Identification and Nomenclature

Choline is a well-characterized small molecule, formally recognized within major biochemical and pharmacological databases. It is assigned the DrugBank Accession Number DB00122 and the Chemical Abstracts Service (CAS) Registry Number 62-49-7.[1] Within the DrugBank classification system, it is categorized as an approved nutraceutical, reflecting its status as an essential nutrient, but it is also designated as investigational, acknowledging its ongoing evaluation for various therapeutic applications.[4]

The molecular formula for the choline cation is consistently reported as C5​H14​NO+.[1] Its average molecular weight is 104.17 g/mol (often specified as 104.1708 g/mol), with a precise monoisotopic mass of approximately 104.1075 Da.[1]

Choline is known by an extensive list of synonyms, a testament to its long history of scientific investigation and its availability in diverse commercial forms. Among the most common are Bilineurine, Choline ion, and (2-Hydroxyethyl)trimethylammonium.[1] Its preferred International Union of Pure and Applied Chemistry (IUPAC) name is

2-Hydroxy-N,N,N-trimethylethan-1-aminium, though the systematic name Ethanaminium, 2-hydroxy-N,N,N-trimethyl- is also widely used in chemical literature.[3] In practical and clinical contexts, choline is often referred to by the name of its associated salt, such as Choline Chloride (CAS 67-48-1) or Choline Bitartrate (CAS 87-67-2), which are common forms used in dietary supplements and research.[9]

Physicochemical Characteristics

Structurally, choline is a quaternary ammonium cation. It is the parent compound of the cholines chemical class, which is characterized by an ethanolamine core where the amino function has three methyl substituents attached to the nitrogen atom.[2] This structural feature is paramount; the presence of four covalent bonds to the nitrogen atom (three to methyl groups and one to the ethyl group) results in a permanent positive charge, regardless of the surrounding pH.[12] This permanent charge is the primary determinant of choline's physicochemical properties and, by extension, its biological behavior.

In its base form (choline hydroxide), it is a viscous, alkaline liquid.[2] However, it is more commonly encountered as a salt, such as choline chloride, which typically appears as white, deliquescent (moisture-absorbing) crystals.[9] A defining characteristic of choline and its simple salts is their high solubility in polar solvents like water and ethanol, and their corresponding insolubility in nonpolar organic solvents such as diethyl ether and chloroform.[2] The melting point varies by form and is often accompanied by decomposition; for example, choline base decomposes around 232-233 °C.[2]

The chemical architecture of choline leads to a highly polar molecule. This is reflected in its low octanol-water partition coefficient (logP), which is estimated to be around -3.6 to -4.7, indicating a strong preference for the aqueous phase.[13] Its standard chemical identifiers, which provide an unambiguous representation of its structure, include the Canonical SMILES string

C[N+](C)(C)CCO and the InChIKey OEYIOHPDSNJKLS-UHFFFAOYSA-N.[5]

The chemical structure of choline is not merely a descriptive feature but the direct determinant of its biological fate and function. Because it exists as a permanently charged, highly polar cation, choline cannot passively diffuse across the lipid-rich, nonpolar environment of biological membranes.[14] This fundamental physicochemical constraint necessitates the evolution of specialized protein-based transport systems to facilitate its movement into cells and across critical biological barriers, such as the intestinal epithelium and the blood-brain barrier.[12] The body's reliance on these transporters—including the high-affinity choline transporter (CHT1) in neurons and choline transporter-like (CTL) proteins in other tissues—creates a crucial point of biological regulation. The expression levels and functional activity of these transporters can become the rate-limiting step for all downstream metabolic processes that depend on choline, most notably the synthesis of the neurotransmitter acetylcholine.[12] Therefore, a direct and unbroken chain of causality links choline's simple chemical structure to its complex pharmacokinetic profile and the sophisticated regulatory mechanisms that govern its availability for essential physiological functions.

Property	Value	Source(s)
DrugBank Accession Number	DB00122	4
CAS Registry Number	62-49-7	1
Molecular Formula (Cation)	C5​H14​NO+	1
Average Molecular Weight	104.17 g/mol	1
Monoisotopic Mass	104.107539075 Da	4
IUPAC Name	2-Hydroxy-N,N,N-trimethylethan-1-aminium	8
Key Synonyms	Bilineurine, Choline ion, (2-Hydroxyethyl)trimethylammonium	1
Canonical SMILES	C[N+](C)(C)CCO	5
InChIKey	OEYIOHPDSNJKLS-UHFFFAOYSA-N	5
Physical Description	Viscous, alkaline liquid (base); White, hygroscopic crystals (salts)	2
Solubility Profile	Easily soluble in water and ethanol; Insoluble in ether, chloroform	2
Melting Point	232-233 °C (decomposes)	2
pKa (Strongest Acidic)	13.9 (at 25 °C)	2
logP	-3.6 to -4.7	13

Core Biological Functions and Mechanisms of Action

Choline's status as an essential nutrient is derived from its central and irreplaceable roles in three fundamental areas of human physiology: maintaining the structural integrity of all cells, facilitating neurotransmission, and contributing to one-carbon metabolism. These functions are not independent but are deeply interconnected, positioning choline as a critical hub of metabolic activity.

Pillar of Cellular Structure: Phospholipid Synthesis

The most quantitatively significant fate of choline in the body is its incorporation into phospholipids, which are the primary building blocks of all biological membranes.[18]

The Kennedy Pathway

Choline is the essential precursor for the de novo synthesis of phosphatidylcholine (PC), which is the single most abundant phospholipid in eukaryotic cell membranes, comprising roughly 50% of their phospholipid mass.[19] The synthesis of PC occurs primarily through the ubiquitously expressed

CDP-choline pathway, also known as the Kennedy pathway.[19] This three-step enzymatic process takes place in the cytoplasm and at the endoplasmic reticulum:

1. Phosphorylation: Choline entering the cell is rapidly phosphorylated by the enzyme choline kinase (CK) to form phosphocholine.[22]
2. Activation: The phosphocholine molecule is then activated by reacting with cytidine triphosphate (CTP), a reaction catalyzed by CTP:phosphocholine cytidylyltransferase (CT), to produce cytidine-5'-diphosphocholine (CDP-choline).[21] This step is the rate-limiting reaction in the pathway.[19]
3. Transfer: Finally, the enzyme cholinephosphotransferase (CPT) catalyzes the transfer of the phosphocholine moiety from CDP-choline to a molecule of diacylglycerol (DAG), yielding a new molecule of PC.[21]

Membrane Integrity and Signaling

The PC synthesized through this pathway is vital for the structural integrity, fluidity, and proper function of cellular and organellar membranes.[23] It is not merely a static structural component; membranes are dynamic environments where PC also serves as a reservoir for the generation of lipid second messengers, such as DAG, which are critical for intracellular signaling cascades.[19]

Sphingomyelin Synthesis

Beyond PC, choline is also integral to the synthesis of sphingomyelin, another crucial membrane phospholipid. Sphingomyelin is particularly abundant in the myelin sheath that insulates nerve axons, making it essential for proper nerve conduction.[12] Its synthesis involves the transfer of the phosphocholine headgroup from PC to a ceramide molecule, a reaction catalyzed by sphingomyelin synthase.[23] This pathway also links choline metabolism to the regulation of ceramide, a potent signaling molecule involved in apoptosis (programmed cell death).[4]

Hepatic Lipid Transport

A critical physiological function of PC synthesis occurs in the liver. PC is an indispensable component for the assembly and secretion of very-low-density lipoproteins (VLDL).[12] VLDL particles act as transport vehicles, packaging triglycerides and cholesterol synthesized in the liver and exporting them into the bloodstream for delivery to peripheral tissues for energy use or storage.[22] When choline intake is inadequate, the rate of PC synthesis in the liver becomes insufficient to support VLDL production. This impairment of VLDL secretion leads directly to the accumulation of fat within liver cells (hepatocytes), a condition known as hepatic steatosis, which is the hallmark of non-alcoholic fatty liver disease (NAFLD).[13]

Keystone of Neurotransmission: Acetylcholine Synthesis

Choline's role in the nervous system is equally fundamental, where it serves as the direct and irreplaceable precursor for the synthesis of the neurotransmitter acetylcholine (ACh).[4]

The Acetylcholine Pathway

The synthesis of ACh occurs within the presynaptic terminals of cholinergic neurons. The enzyme choline acetyltransferase (CAT) catalyzes the reaction, transferring an acetyl group from acetyl-coenzyme A (acetyl-CoA), which is generated in mitochondria, to a molecule of choline.[16] The newly synthesized ACh is then packaged into synaptic vesicles for storage and subsequent release into the synaptic cleft upon neuronal firing.[17]

Rate-Limiting Transport

The entire process of ACh synthesis is critically dependent on the availability of extracellular choline. As a charged molecule, choline cannot freely enter neurons. Its uptake is mediated by a specific, sodium-dependent, high-affinity choline transporter (CHT1).[12] The activity of this transporter is the primary

rate-limiting step in the synthesis of ACh. This means that the brain's ability to produce this vital neurotransmitter is directly governed by the efficiency of choline transport into neurons, making the systemic availability of choline a crucial factor for maintaining proper cholinergic function.[12]

Physiological Roles of Acetylcholine

ACh is one of the most important neurotransmitters in both the central and peripheral nervous systems. It plays a pivotal role in a vast array of physiological processes, including higher cognitive functions like memory and learning, mood regulation, muscle contraction at the neuromuscular junction, and the control of numerous autonomic functions such as heart rate and digestion.[12]

Emerging Direct Signaling Role

While choline's signaling role has traditionally been viewed as indirect (via its conversion to ACh or PC), emerging evidence indicates a more direct function. Recent studies have identified that choline itself can act as an intracellular messenger by binding to and activating Sigma-1 receptors (Sigma-1R), which are located on the endoplasmic reticulum membrane. This interaction enhances intracellular calcium signaling, suggesting a novel pathway through which extracellular stimuli can be transduced into cellular responses, independent of choline's other metabolic fates.[12]

Hub of Metabolism: One-Carbon Pool and Methyl Donation

The third major function of choline places it at the center of cellular metabolism, where it serves as a key source of methyl groups, interfacing directly with folate and methionine metabolism.

Oxidation to Betaine

Within the inner mitochondrial membrane of the liver and kidneys, choline undergoes an irreversible, two-step enzymatic oxidation to form betaine, also known as trimethylglycine.[13] This process is catalyzed sequentially by choline oxidase and betaine aldehyde dehydrogenase.[25]

The Betaine-Homocysteine Methyltransferase (BHMT) Pathway

Betaine is a potent methyl donor that plays a critical role in the one-carbon metabolism cycle. Specifically, the liver-specific enzyme betaine-homocysteine methyltransferase (BHMT) utilizes a methyl group from betaine to remethylate the amino acid homocysteine, converting it back to methionine.[4] Methionine is subsequently activated to form

S-adenosylmethionine (SAM), which is the universal methyl donor for thousands of critical methylation reactions throughout the body.[12] These reactions include the methylation of DNA and histones, which are fundamental epigenetic mechanisms that regulate gene expression, as well as the synthesis of numerous essential molecules.[31]

Interplay with Folate Metabolism

The BHMT pathway for homocysteine remethylation operates in parallel to a more widely distributed pathway that uses a methyl group derived from folate (5-methyltetrahydrofolate).[31] These two pathways are metabolically interconnected. When the supply of folate is limited, the body's reliance on the choline-derived betaine pathway increases to maintain methionine synthesis and control homocysteine levels.[23] This metabolic flexibility underscores the critical interrelationship between these nutrients. Maintaining low levels of homocysteine is clinically important, as elevated homocysteine is a well-established independent risk factor for cardiovascular disease.[4]

The existence of these three distinct, vital, and often competing metabolic fates for choline positions it as a central point of metabolic triage. The body must dynamically allocate the available pool of choline to where it is most needed: for building new cell membranes (structural), for synthesizing neurotransmitters (signaling), or for donating methyl groups (metabolic). During periods of rapid growth, pregnancy, or tissue repair, the demand for PC synthesis is immense.[10] During intense cognitive activity, ACh synthesis is prioritized in the brain.[16] In states of nutritional stress, such as folate deficiency, the oxidation of choline to betaine becomes more critical to support the one-carbon pool.[23] When choline intake is deficient, the body faces a metabolic crisis and must "choose" which function to sacrifice. Evidence suggests that maintaining stable plasma choline concentrations, likely to preserve essential ACh synthesis, is prioritized, even at the cost of breaking down existing membrane phospholipids to liberate free choline. This catabolic process ultimately leads to compromised cell membrane integrity, apoptosis, and the organ damage (liver and muscle) that clinically defines choline deficiency.[4] This principle explains why the primary symptoms of choline deficiency are organ-specific damage rather than immediate, catastrophic neurological failure. Understanding how the body prioritizes the allocation of this limited resource under different physiological and pathological conditions is therefore key to interpreting the diverse clinical manifestations of its deficiency and identifying the most promising targets for its therapeutic use.

Pharmacokinetics of Choline and its Metabolites (ADME)

The journey of choline through the body—its absorption, distribution, metabolism, and excretion (ADME)—is complex and heavily influenced by the chemical form in which it is ingested. Understanding these pharmacokinetic processes is crucial for optimizing dietary recommendations and developing effective therapeutic strategies.

Absorption and Bioavailability

Dietary choline is not a single entity but exists in several forms, which can be broadly categorized as water-soluble (free choline, phosphocholine, glycerophosphocholine) and lipid-soluble (phosphatidylcholine, sphingomyelin).[23] This distinction is the primary determinant of their absorption pathway and subsequent bioavailability.

Water-soluble forms of choline are absorbed from the small intestine by specific carrier-mediated transport proteins. Once absorbed into the enterocytes, they enter the portal circulation and are transported directly to the liver, which is the central organ for choline metabolism.[15]

Lipid-soluble forms, primarily phosphatidylcholine (PC), undergo a different fate. Pancreatic and mucosal enzymes, such as phospholipases, can hydrolyze PC in the intestinal lumen, liberating free choline that is then absorbed via the water-soluble pathway.[15] However, a significant portion of dietary PC can be absorbed intact. This intact PC is incorporated into chylomicrons, the large lipoprotein particles assembled in enterocytes to transport dietary fats. These chylomicrons are secreted into the lymphatic system, thereby bypassing the liver's first-pass metabolism and delivering PC directly to the systemic circulation and peripheral tissues.[15]

A critical factor influencing choline bioavailability is the gut microbiome. Intestinal bacteria can extensively metabolize free choline before it is absorbed, converting it into trimethylamine (TMA).[28] This TMA is readily absorbed, enters the portal circulation, and is transported to the liver. There, it is oxidized by flavin-containing monooxygenase 3 (FMO3) into

trimethylamine N-oxide (TMAO), a metabolite that has been associated in numerous epidemiological studies with an increased risk of atherosclerosis and cardiovascular disease.[32]

Comparative pharmacokinetic studies have illuminated the practical consequences of these different pathways. Supplementation with water-soluble choline salts, such as choline bitartrate, leads to a rapid increase in plasma choline concentrations, with a peak occurring at approximately 1 to 2 hours post-ingestion. However, this is accompanied by a sharp and significant rise in plasma TMAO levels.[34] In stark contrast, supplementation with lipid-soluble PC, derived from sources like krill oil or egg yolk, results in a slower, more gradual, and sustained increase in plasma choline, with a peak concentration reached much later, at around 3 to 4 hours. Critically, this form of supplementation does not lead to a significant increase in the production of TMAO.[34]

This differential fate of choline based on its ingested form has profound clinical implications. The choice of choline supplement is not trivial; it is a critical variable that should be tailored to the therapeutic goal. If the objective is a rapid elevation of systemic choline, a water-soluble salt might be considered. However, for long-term supplementation aimed at supporting structural or metabolic health (e.g., in NAFLD or for chronic cognitive support), a PC-based form appears theoretically superior. This is because it provides a more sustained release of choline while minimizing the production of TMAO, a metabolite with potential adverse cardiovascular effects. This moves the clinical question from a simple consideration of "how much choline?" to a more sophisticated analysis of "which form of choline is optimal for a specific therapeutic outcome?".

Distribution, Tissue Uptake, and Storage

Once in the systemic circulation, choline is distributed throughout the body. The liver plays a central role, taking up the majority of choline from the portal blood and storing it, primarily by converting it into PC.[10] This hepatic pool of PC serves as a reservoir that can be hydrolyzed to release free choline back into circulation as needed.

Distribution to the brain is a tightly regulated process. Free choline is transported across the blood-brain barrier by a specific, high-capacity carrier-mediated transport system.[15] The rate of this transport is proportional to the plasma choline concentration, ensuring that the central nervous system has a steady supply for the synthesis of acetylcholine and membrane phospholipids.[15]

During pregnancy, choline distribution is dramatically altered to meet the high demands of the developing fetus. Choline is actively transported across the placenta, resulting in concentrations in the amniotic fluid that are up to ten times higher than those in the maternal blood.[10] This highlights the critical importance of choline for fetal neurodevelopment and overall growth.

Metabolism and Excretion

The metabolism of choline is complex, with its fate determined by the needs of individual tissues. The three primary metabolic pathways are:

1. Phosphorylation via the Kennedy pathway to form PC, which occurs in all nucleated cells.[15]
2. Acetylation by choline acetyltransferase in cholinergic neurons to form acetylcholine.[17]
3. Irreversible oxidation in the mitochondria of the liver and kidneys to form betaine.[15]

Excretion of choline is a minor pathway for its elimination. A small amount of unmetabolized free choline is excreted in the urine. However, the vast majority of ingested choline is either incorporated into phospholipids, converted to acetylcholine, or oxidized to betaine and its downstream metabolites within the one-carbon cycle.[10]

Clinical Significance and Therapeutic Landscape

Choline's integral roles in cellular structure, neurotransmission, and metabolism mean that its availability has profound implications for human health and disease. Research has established a clear link between choline deficiency and organ dysfunction, while ongoing clinical trials are exploring its therapeutic potential across a wide spectrum of conditions.

Choline Deficiency: Pathophysiology and Clinical Manifestations

Although the human body can synthesize small amounts of choline de novo, this endogenous production is insufficient to meet physiological needs, making dietary intake essential.[8] When dietary intake is inadequate, a state of choline deficiency can develop, leading to distinct clinical pathologies.

Non-Alcoholic Fatty Liver Disease (NAFLD)

The most well-documented consequence of choline deficiency in humans is the development of non-alcoholic fatty liver disease (NAFLD) and associated liver damage.[13] Controlled feeding studies in humans have unequivocally demonstrated that depriving healthy individuals of dietary choline leads to fat accumulation in the liver (steatosis) and elevated liver enzymes, which are markers of liver cell death. These signs of liver damage are reversed upon reintroduction of choline into the diet.[25] The underlying mechanism is the impairment of VLDL synthesis and secretion due to an insufficient supply of phosphatidylcholine (PC), which is essential for packaging and exporting triglycerides from the liver.[25]

Muscle Damage

In addition to liver damage, choline deficiency can also lead to skeletal muscle damage (myopathy). This is clinically identified by an increase in serum levels of the enzyme creatine kinase, which is released from damaged muscle cells.[25]

Factors Influencing Individual Requirement

Susceptibility to choline deficiency is not uniform across the population. Several factors significantly modulate an individual's dietary requirement for choline:

• Genetics: Single nucleotide polymorphisms (SNPs) in genes involved in choline and one-carbon metabolism are key determinants of susceptibility. Variations in the phosphatidylethanolamine N-methyltransferase (PEMT) gene are particularly important. The PEMT enzyme catalyzes the de novo synthesis of PC in the liver, providing an endogenous source of choline. Individuals with less active genetic variants of PEMT are less able to compensate for low dietary intake and have a significantly higher dietary choline requirement.[25]
• Hormonal Status: There is a pronounced sex-specific difference in choline requirements, driven by estrogen. Estrogen induces the expression of the PEMT gene. Consequently, premenopausal women have a greater capacity for endogenous choline synthesis and are relatively protected from developing organ dysfunction on a low-choline diet. In contrast, postmenopausal women and men have a higher dietary requirement and are much more likely to develop NAFLD and muscle damage when choline intake is insufficient.[23]

Therapeutic Potential and Clinical Trials

Given its fundamental biological roles, choline and its derivatives are being actively investigated as therapeutic agents for a variety of conditions.

NAFLD Treatment

Building on the established link between choline deficiency and NAFLD, recent clinical trials have explored choline supplementation as a treatment. A randomized controlled study (NCT05200156) provided compelling evidence for its efficacy. After 12 weeks of supplementation, patients with NAFLD showed significant improvements in hepatic steatosis (measured by controlled attenuation parameter), fibrosis scores, markers of oxidative stress (TBARS), and inflammatory markers (leptin), as well as reductions in liver enzymes and improvements in lipid profiles.[39] Furthermore, a large cross-sectional analysis from the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) found that lower dietary choline intake was significantly associated with more severe liver fibrosis in postmenopausal women with NAFLD, reinforcing the importance of adequate choline in this high-risk group.[42]

Cognitive Health and Alzheimer's Disease (AD)

The role of choline as the direct precursor to acetylcholine provides a strong biological rationale for its investigation in Alzheimer's disease, a condition characterized by a profound deficit in cholinergic neurotransmission.[4] Recent research has expanded this rationale, demonstrating that low circulating choline levels are associated with the core pathologies of AD, including greater amyloid plaque and tau tangle accumulation in the brain.[43] This suggests that the therapeutic paradigm for choline in AD is evolving. It is moving away from a simplistic "more precursor equals more neurotransmitter" model toward a more sophisticated understanding of choline's role in maintaining the fundamental structural and metabolic health of neurons. Early therapeutic strategies focused on boosting ACh levels with limited success.[26] However, newer research and ongoing clinical trials are investigating a different mechanism: that choline supports neuronal health by shoring up membrane integrity and normalizing lipid homeostasis, thereby potentially slowing the cascade of events that leads to neurodegeneration. This is exemplified by the rationale for trial NCT05880849, which is not focused on ACh but on using choline to normalize the Kennedy pathway for lipid synthesis in individuals with the high-risk APOE4 gene.[45]

• Observational Data: Large prospective cohort studies have reported that higher dietary choline intake, in the range of 400 mg/day, is associated with a lower risk of developing dementia and AD.[47]
• Clinical Trials: The evidence from intervention trials is varied and often involves different forms of choline:
• Choline Bitartrate: The ongoing trial NCT05880849 is specifically testing the safety and biochemical effects of choline bitartrate in a population at high genetic risk for AD (APOE4 carriers), with the primary goal of assessing its impact on brain lipid metabolism.[45]
• Choline Alfoscerate (alpha-GPC): The ASCOMALVA trial found that combining choline alfoscerate with a standard cholinesterase inhibitor was more effective at slowing brain atrophy than the inhibitor alone in AD patients with cerebrovascular damage. Another trial is planned to evaluate its efficacy in mild cognitive impairment (MCI).[48]
• Citicoline (CDP-Choline): Studies suggest that citicoline, when used as an adjunct therapy with standard AD medications, may improve cognitive scores in patients with mixed dementia and AD.[49]
• Egg-Yolk Choline: A randomized trial in older adults with subjective memory complaints found that choline supplementation led to a statistically significant improvement in verbal memory, though this isolated finding requires cautious interpretation as it was not corrected for multiple comparisons.[50]

Fetal Development and Fetal Alcohol Spectrum Disorders (FASD)

Maternal choline intake is critically important for fetal brain development.[37] This has led to investigations of choline as a potential intervention for neurodevelopmental disorders. A cumulative analysis of three randomized controlled trials (NCT01149538, NCT02735473) showed that daily supplementation with 500 mg of choline improved a specific measure of memory (elicited imitation) in preschool-aged children with FASD, with the greatest benefit observed in younger children.[52]

Other Investigational Uses

The therapeutic landscape for choline is broad and expanding. Clinical trials have been completed or are ongoing to investigate its role in:

• COVID-19 and Long-Haul COVID-19: A Phase 1 trial for acute COVID-19 has been completed, and a trial for Long-Haul COVID-19 is currently recruiting participants.[53]
• Alcohol Dependency: A completed Phase 4 trial has explored the use of citicoline for alcohol dependence.[55]
• Diagnostic Imaging: Carbon-11 labeled choline ($^{11}$C-Choline) is used as a tracer in Positron Emission Tomography (PET) scanning for the diagnostic imaging of certain cancers, such as esophageal and prostate cancer, due to the increased membrane synthesis in rapidly proliferating cancer cells.[56]

Indication	ClinicalTrials.gov ID	Phase	Status	Purpose	Choline Form Used	Key Findings / Objectives
Alzheimer's Disease (Pre-symptomatic)	NCT05880849	Not Applicable	Recruiting	Treatment	Choline Bitartrate	To test safety and effects on brain lipid metabolism in APOE4 carriers.45
Mild Cognitive Impairment (MCI)	EudraCT: 2020-000576-38	Not Applicable	Recruiting	Treatment	Choline Alfoscerate	To evaluate efficacy in slowing brain atrophy and cognitive decline in MCI with vascular damage.48
Non-Alcoholic Fatty Liver Disease (NAFLD)	NCT05200156	Not Applicable	Completed	Treatment	Phosphatidyl Choline	To assess the impact on liver echogenicity, liver function, lipid profile, and oxidative stress.41
Fetal Alcohol Spectrum Disorders (FASD)	NCT01149538, NCT02735473	Not Applicable	Completed	Treatment	Choline (Bitartrate)	Demonstrated improved memory performance in preschool children with FASD.52
Long-Haul COVID-19	Not specified	Not Available	Recruiting	Treatment	Choline	To investigate choline's potential in treating post-acute sequelae of SARS-CoV-2 infection.53
COVID-19	Not specified	1	Completed	Treatment	Choline	Early-phase trial for acute SARS-CoV-2 infection.54
Alcohol Dependency	NCT02074735	4	Completed	Treatment	Citicoline	To evaluate citicoline for alcohol dependence.55
Esophageal Cancer	NCT01051479	1	Completed	Diagnostic	$^{11}$C-Choline	Pilot study of $^{11}$C-Choline PET-CT imaging in esophageal cancer.56

Nutritional and Dietary Considerations

While choline can be synthesized endogenously, the amount is insufficient to meet human needs, making it an essential dietary nutrient. Ensuring adequate intake through diet and, when necessary, supplementation is critical for maintaining health and preventing deficiency-related diseases.

Dietary Sources

Choline is present in a wide variety of foods, though its concentration varies considerably. The richest and most bioavailable sources are typically animal-based products.[58]

• Primary Animal Sources: The most concentrated sources of choline include beef liver (approximately 431 mg per 100g, cooked), egg yolks (a single large hard-boiled egg contains about 226 mg), various meats, poultry, fish, and dairy products.[23]
• Primary Plant Sources: For those following plant-based diets, good sources include cruciferous vegetables like broccoli and Brussels sprouts, certain beans and legumes, nuts (e.g., almonds), seeds, and whole grains like quinoa.[23] Soybeans and wheat germ are also particularly rich in choline.[58]
• Food Additives: Lecithin, which is primarily composed of phosphatidylcholine, is commonly derived from soybeans and used as an emulsifying agent in many processed foods, contributing to total choline intake.[27]

Dietary choline is present in both water-soluble forms (free choline, phosphocholine) and lipid-soluble forms (phosphatidylcholine, sphingomyelin). Human breast milk, for instance, is rich in water-soluble forms, whereas the adult diet typically derives more choline from lipid-soluble forms found in foods like eggs and meat.[33]

Adequate Intake (AI) and Tolerable Upper Intake Level (UL)

Due to a lack of sufficient data to establish a formal Recommended Dietary Allowance (RDA), health organizations like the U.S. Institute of Medicine (IOM) and the European Food Safety Authority (EFSA) have set values for Adequate Intake (AI). The AI is an estimate of the average daily intake level assumed to be adequate, and it is primarily based on the amount needed to prevent liver damage in controlled studies.[23]

• Adequate Intake (AI) for Adults:
• Men: 550 mg/day [13]
• Women: 425 mg/day [13]
• Increased Needs During Pregnancy and Lactation: The demand for choline increases significantly during pregnancy and lactation to support rapid cell division and neurodevelopment in the fetus and infant.
• Pregnancy: 440-450 mg/day [23]
• Lactation: 550 mg/day [23]
• Tolerable Upper Intake Level (UL): To prevent adverse effects from excessive intake, a Tolerable Upper Intake Level (UL) has been established. The UL is the highest level of daily nutrient intake that is likely to pose no risk of adverse health effects for almost all individuals in the general population.
• UL for Adults: 3.5 g/day (3,500 mg/day) [24]

It is important to note that despite these recommendations, population surveys indicate that a majority of people, including pregnant women, do not meet the AI for choline, highlighting a potential public health concern.[51]

Safety, Toxicology, and Drug Interactions

While choline is an essential nutrient, excessive intake can lead to adverse effects. A comprehensive understanding of its safety profile is essential for both dietary guidance and therapeutic use.

Adverse Effects of Supplementation

Consumption of choline within the range of typical dietary intake is generally considered safe. However, supplementation, particularly at high doses, can lead to a range of adverse effects.

• Common Side Effects: At normal supplemental doses, some individuals may experience gastrointestinal discomfort, including stomachache, diarrhea, or loose stools.[26]
• High-Dose Effects: As intake approaches or exceeds the Tolerable Upper Intake Level (UL) of 3.5 g/day, more pronounced and systemic side effects can occur. These are primarily cholinergic in nature and include a characteristic fishy body odor, vomiting, excessive sweating (diaphoresis), and increased salivation.[8] The fishy odor is caused by the excessive production and excretion of trimethylamine (TMA), a bacterial metabolite of choline.[60]

Toxicity and Overdose

Very high doses of choline (e.g., greater than 7.5 g/day) can lead to more severe toxic effects. The most significant of these is hypotension (a sharp drop in blood pressure).[8] High intake has also been associated with liver problems and may induce or worsen depression in susceptible individuals. For this reason, choline supplementation should be used with caution in individuals with bipolar disorder.[26]

The TMAO Hypothesis and Cardiovascular Risk

One of the most complex and actively researched areas of choline safety involves its relationship with cardiovascular disease (CVD) via the metabolite trimethylamine N-oxide (TMAO). This presents a clinical and nutritional paradox.

• The Pathway: Dietary choline is metabolized by certain gut bacteria to produce TMA. TMA is absorbed into the bloodstream and transported to the liver, where it is converted by the FMO3 enzyme into TMAO.[32]
• The Association: A growing body of evidence from large observational studies has linked higher circulating levels of TMAO with an increased risk of major adverse cardiovascular events, including heart attack and stroke.[32] This suggests that a diet high in choline-rich foods, such as red meat and eggs, could paradoxically increase CVD risk by fueling TMAO production.
• The Contradiction: However, the evidence is not entirely consistent. The relationship is complex, as other studies have found that higher dietary choline intake is associated with a lower risk of ischemic stroke and reduced blood pressure.[32] This highlights that the net effect of choline intake on cardiovascular health may depend on a variety of factors, including an individual's gut microbiome composition, genetics (e.g., FMO3 activity), and the overall dietary pattern.

This choline-TMAO paradox represents a major challenge in nutritional science. It creates a dilemma where an essential nutrient, whose deficiency causes severe organ damage, has a metabolic byproduct that is implicated as a pro-atherosclerotic molecule. This complicates public health messaging and dietary recommendations. Future research must focus on resolving this paradox, potentially by identifying dietary strategies or specific forms of choline (such as phosphatidylcholine, which appears to generate less TMAO than choline salts) that can provide the benefits of choline while minimizing the potential risks associated with TMAO.[34] This could involve promoting plant-based choline sources, developing next-generation supplements, or exploring interventions that modulate the gut microbiome to reduce TMA production.

Known Interactions

The data on specific drug-choline interactions are limited.

• One source suggests a potential interaction with methotrexate, a medication used in oncology and rheumatology, although the mechanism and clinical significance are not well-defined.[62]
• While not direct interactions with choline, it is plausible that high-dose choline supplementation could potentiate the effects of cholinergic drugs (e.g., cholinesterase inhibitors like donepezil) or interfere with the action of anticholinergic drugs. A database of interactions for acetylcholine lists numerous theoretical interactions with drugs that could increase the risk of adverse cholinergic effects (e.g., beta-blockers) or decrease efficacy (e.g., some antibiotics).[63] These are relevant considerations when choline is used with the intent of boosting cholinergic activity.
• Most sources state that choline is not known to have significant interactions with medications, but caution that patients should always inform their healthcare providers about any supplements they are taking.[61]

Synthesis and Future Directions

Choline (DB00122) is an essential, multifaceted nutrient whose physiological importance extends far beyond its historical classification as a B-vitamin-like compound. It is a fundamental building block for life, serving as a critical component of cell membranes, the precursor to the vital neurotransmitter acetylcholine, and a key player in the intricate network of one-carbon metabolism. The evidence synthesized in this report underscores that both deficiency and excess can have significant health consequences, and that the optimal intake and therapeutic application of choline are subject to a complex interplay of genetics, hormonal status, diet, and the gut microbiome.

The clinical landscape for choline is evolving rapidly. Its established role in preventing and reversing deficiency-induced non-alcoholic fatty liver disease (NAFLD) is now being translated into promising therapeutic trials showing improvements in hepatic steatosis and fibrosis. In the realm of neuroscience, the research paradigm for choline in Alzheimer's disease is shifting from a simple neurotransmitter-precursor model to a more nuanced approach focused on its role in maintaining neuronal membrane integrity and lipid homeostasis, particularly in genetically susceptible individuals. Furthermore, its demonstrated benefits for memory in children with fetal alcohol spectrum disorders highlight its critical role in neurodevelopment.

Despite this progress, several key challenges and critical questions remain, which will define the future directions of choline research:

1. Resolving the Choline-TMAO Paradox: The most pressing challenge is to reconcile the essential need for dietary choline with the potential cardiovascular risk posed by its metabolite, TMAO. Future research must focus on strategies to uncouple these effects. This includes conducting large-scale clinical trials to clarify the net impact of different choline-rich dietary patterns on cardiovascular outcomes and developing targeted interventions, such as promoting specific forms of choline (e.g., phosphatidylcholine) that have a lower TMAO conversion rate or modulating the gut microbiome to reduce TMA production.
2. Defining Personalized Choline Requirements: The current "one-size-fits-all" Adequate Intake (AI) levels are a blunt instrument. A major goal for nutritional science is to move towards personalized choline recommendations. This will require integrating data on an individual's genetic polymorphisms (e.g., in PEMT and other metabolic genes), hormonal status (e.g., pre- vs. post-menopause), and microbiome composition to more accurately predict their dietary needs and susceptibility to deficiency.
3. Clarifying Therapeutic Efficacy with Precision: While promising, the therapeutic potential of choline requires validation through large-scale, rigorously designed randomized controlled trials (RCTs). These trials must be designed to definitively establish the efficacy of specific forms and doses of choline in well-defined patient populations for conditions like NAFLD and Alzheimer's disease. A key focus should be on identifying biomarkers that can predict which patient subgroups are most likely to respond to choline-based therapies.
4. Exploring Novel Biological Mechanisms: The recent discovery of choline's direct signaling role via the Sigma-1 receptor opens up a new avenue of investigation. Further research is needed to elucidate the physiological and pathological implications of this pathway and to explore whether it represents a novel target for therapeutic intervention.

In conclusion, choline stands at a critical intersection of nutrition, metabolism, and neuroscience. It is not merely a supplement but a powerful biological molecule with significant potential for both disease prevention and targeted therapy. Realizing this potential will depend on a continued and sophisticated scientific effort to navigate its complexities and translate fundamental biological understanding into precise and effective clinical applications.

Works cited

1. Choline | CAS 62-49-7 | SCBT - Santa Cruz Biotechnology, accessed September 1, 2025, https://www.scbt.com/p/choline-62-49-7
2. CHOLINE | 62-49-7 - ChemicalBook, accessed September 1, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1139255.htm
3. Choline - CAS Common Chemistry, accessed September 1, 2025, https://commonchemistry.cas.org/detail?cas_rn=62-49-7
4. Choline: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/drugs/DB00122
5. CAS 62-49-7 Choline - Metabolites / Alfa Chemistry, accessed September 1, 2025, https://metabolites.alfa-chemistry.com/product/choline-cas-62-49-7-408690.html
6. Choline | CAS No- 62-49-7 - Simson Pharma Limited, accessed September 1, 2025, https://www.simsonpharma.com/product/choline
7. Choline (Compound) - Exposome-Explorer, accessed September 1, 2025, http://exposome-explorer.iarc.fr/compounds/2363
8. Choline - Wikipedia, accessed September 1, 2025, https://en.wikipedia.org/wiki/Choline
9. Choline Chloride | C5H14NO.Cl | CID 6209 - PubChem, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Choline-Chloride
10. Choline Bitartrate | C9H19NO7 | CID 6900 - PubChem, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Choline-Bitartrate
11. en.wikipedia.org, accessed September 1, 2025, https://en.wikipedia.org/wiki/Choline#:~:text=as%20a%20nutrient-,Chemistry,to%20the%20same%20nitrogen%20atom.
12. Choline—An Essential Nutrient with Health Benefits and a Signaling ..., accessed September 1, 2025, https://www.mdpi.com/1422-0067/26/15/7159
13. Showing Compound Choline (FDB000710) - FooDB, accessed September 1, 2025, https://foodb.ca/compounds/FDB000710
14. Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, Metabolism, and Elimination | Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition | AccessMedicine, accessed September 1, 2025, https://accessmedicine.mhmedical.com/content.aspx?bookid=3191§ionid=267905627
15. Choline - Dietary Reference Intakes for Thiamin, Riboflavin, Niacin ..., accessed September 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK114308/
16. Acetylcholine Synthesis and Metabolism - Sigma-Aldrich, accessed September 1, 2025, https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/research-and-disease-areas/cell-signaling/acetylcholine-synthesis-and-metabolism
17. Physiology, Acetylcholine - StatPearls - NCBI Bookshelf, accessed September 1, 2025, https://www.ncbi.nlm.nih.gov/books/NBK557825/
18. (PDF) Choline Transport for Phospholipid Synthesis - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/7145127_Choline_Transport_for_Phospholipid_Synthesis
19. The Major Sites of Cellular Phospholipid Synthesis and Molecular Determinants of Fatty Acid and Lipid Head Group Specificity - PMC, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC124149/
20. Metabolic labeling and direct imaging of choline phospholipids in vivo - PNAS, accessed September 1, 2025, https://www.pnas.org/doi/10.1073/pnas.0907864106
21. Structural basis for catalysis and selectivity of phospholipid synthesis by eukaryotic choline-phosphotransferase - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/380600609_Structural_basis_for_catalysis_and_selectivity_of_phospholipid_synthesis_by_eukaryotic_choline-phosphotransferase
22. Phospholipid Biosynthesis – AOCS, accessed September 1, 2025, https://www.aocs.org/resource/phospholipid-biosynthesis/
23. Choline - Health Professional Fact Sheet - NIH Office of Dietary Supplements, accessed September 1, 2025, https://ods.od.nih.gov/factsheets/Choline-HealthProfessional/
24. An Introduction to the Nutrition and Metabolism of Choline - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/223964676_An_Introduction_to_the_Nutrition_and_Metabolism_of_Choline
25. Choline | Linus Pauling Institute | Oregon State University, accessed September 1, 2025, https://lpi.oregonstate.edu/mic/other-nutrients/choline
26. Choline - Content - Health Encyclopedia - University of Rochester Medical Center, accessed September 1, 2025, https://www.urmc.rochester.edu/encyclopedia/content?contentid=choline&contenttypeid=19
27. Choline | Essential Nutrient, Vitamin B Complex, Brain Function | Britannica, accessed September 1, 2025, https://www.britannica.com/science/choline
28. Choline: An Essential Nutrient for Human Health - PMC, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10343572/
29. Choline and betaine in health and disease - PubMed, accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/20446114/
30. (PDF) Choline and betaine in health and disease - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/44576640_Choline_and_betaine_in_health_and_disease
31. Choline Metabolism Provides Novel Insights into Non-alcoholic Fatty Liver Disease and its Progression - PMC - PubMed Central, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3601486/
32. Choline - The Nutrition Source, accessed September 1, 2025, https://nutritionsource.hsph.harvard.edu/choline/
33. Dietary Choline Intake: Current State of Knowledge Across the Life Cycle - PMC, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6213596/
34. Plasma Kinetics of Choline and Choline Metabolites After A Single Dose of SuperbaBoostTM Krill Oil or Choline Bitartrate in Healthy Volunteers - PMC, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6835836/
35. Abstract P397: Choline Metabolites Are Associated With Non-Alcoholic Fatty Liver Disease: A Coronary Artery Risk Development in Young Adults (CARDIA) Study | Circulation, accessed September 1, 2025, https://www.ahajournals.org/doi/abs/10.1161/circ.149.suppl_1.P397
36. (PDF) Differential metabolism of choline supplements in adult volunteers - ResearchGate, accessed September 1, 2025, https://www.researchgate.net/publication/353377123_Differential_metabolism_of_choline_supplements_in_adult_volunteers
37. The Ups and Downs of Choline Supplements - McGill University, accessed September 1, 2025, https://www.mcgill.ca/oss/article/medical-student-contributors/ups-and-downs-choline-supplements
38. Betaine and Choline Improve Lipid Homeostasis in Obesity by Participation in Mitochondrial Oxidative Demethylation - Frontiers, accessed September 1, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2018.00061/full
39. (PDF) The impact of choline supplementation on oxidative stress ..., accessed September 1, 2025, https://www.researchgate.net/publication/394528340_The_impact_of_choline_supplementation_on_oxidative_stress_and_clinical_outcomes_among_patients_with_non-alcoholic_fatty_liver_disease_a_randomized_controlled_study
40. The impact of choline supplementation on oxidative stress and clinical outcomes among patients with non-alcoholic fatty liver disease: a randomized controlled study - PMC - PubMed Central, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12361734/
41. Study Details | Impact Of Choline in Patients With NAFLD - ClinicalTrials.gov, accessed September 1, 2025, https://clinicaltrials.gov/study/NCT05200156?term=AREA%5BConditionSearch%5D(%22Visceral%20Steatosis%22)%20AND%20AREA%5BInterventionSearch%5D(%22Choline%22)&rank=7
42. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease., accessed September 1, 2025, https://scholars.duke.edu/display/pub768488
43. New research links low choline levels in blood to Alzheimer's ..., accessed September 1, 2025, https://news.asu.edu/20230807-new-research-links-low-choline-levels-blood-alzheimers-disease-progression
44. Association between choline supplementation and Alzheimer's disease risk: a systematic review protocol - Frontiers, accessed September 1, 2025, https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2023.1242853/full
45. Choline Effects - Pre-symptomatic AD - Clinical Trials, accessed September 1, 2025, https://uth.trialstoday.org/trial/NCT05880849
46. Choline in Alzheimer Disease - Clinical Trials Registry - ICH GCP, accessed September 1, 2025, https://ichgcp.net/amp/clinical-trials-registry/NCT05880849
47. New Study: higher choline intake lowers the risk of dementia, Alzheimer's, & cognitive decline - Food for the Brain, accessed September 1, 2025, https://foodforthebrain.org/new-study-higher-choline-intake-lowers-the-risk-of-dementia-alzheimers-cognitive-decline/
48. Effect of Treatment of the Cholinergic Precursor Choline Alphoscerate in Mild Cognitive Dysfunction: A Randomized Controlled Trial - MDPI, accessed September 1, 2025, https://www.mdpi.com/1648-9144/60/6/925
49. Citicoline: A Cholinergic Precursor with a Pivotal Role in Dementia and Alzheimer's Disease, accessed September 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11307077/
50. Could supplementing with choline boost cognitive ... - Examine.com, accessed September 1, 2025, https://examine.com/research-feed/study/dEPW39/
51. Eye on Nutrition: Choline | WIC Works Resource System - USDA, accessed September 1, 2025, https://wicworks.fns.usda.gov/resources/eye-nutrition-choline
52. Choline enhances elicited imitation memory performance in preschool children with prenatal alcohol exposure: a cumulative report of 3 randomized controlled trials - PubMed, accessed September 1, 2025, https://pubmed.ncbi.nlm.nih.gov/39956364/
53. Long-Haul COVID-19 Recruiting Phase Trials for Choline (DB00122) | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/indications/DBCOND0151631/clinical_trials/DB00122?status=recruiting
54. COVID - 19 Completed Phase 1 Trials for Choline (DB00122) | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/indications/DBCOND0128668/clinical_trials/DB00122?phase=1&status=completed
55. Choline Completed Phase 4 Trials for Alcohol Dependency Treatment | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/drugs/DB00122/clinical_trials?conditions=DBCOND0071586&phase=4&purpose=treatment&status=completed
56. Choline Completed Phase 1 Trials for Esophageal Cancer Diagnostic | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/drugs/DB00122/clinical_trials?conditions=DBCOND0028460&phase=1&purpose=diagnostic&status=completed
57. Choline C-11 | C5H14NO+ | CID 449688 - PubChem, accessed September 1, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Choline-C-11
58. Choline - Nutrient Reference Values - Eat For Health, accessed September 1, 2025, https://www.eatforhealth.gov.au/nutrient-reference-values/nutrients/choline
59. Food Sources Contributing to Intake of Choline and Individual Choline Forms in a Norwegian Cohort of Patients With Stable Angina Pectoris - Frontiers, accessed September 1, 2025, https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.676026/full
60. USDA Database for the Choline Content of Common ... - USDA ARS, accessed September 1, 2025, https://www.ars.usda.gov/ARSUserFiles/80400525/data/choline/choln02.pdf
61. Choline - Consumer, accessed September 1, 2025, https://ods.od.nih.gov/factsheets/Choline-Consumer/
62. Choline - WebMD, accessed September 1, 2025, https://www.webmd.com/vitamins-and-supplements/choline
63. Acetylcholine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 1, 2025, https://go.drugbank.com/drugs/DB03128